Free Newsletter
Pharma money on display for Dems
Big Pharma has ponied up big bucks to help finance the Democratic National Convention--and the companies have sent their CEOs to Denver to put their mouths where their money is.
The list of health-oriented sponsors reads like a roll call of drugmakers: Merck, Amgen, Pfizer, AstraZeneca, Novartis, Mylan, Abbott and Eli Lilly. Five of those companies--Pfizer, AstraZeneca, Lilly, Amgen and Merck--have put CEO power behind their cash. AstraZeneca and Lilly dispatched their CEOs--David Brennan (photo) and John Lechleiter (photo), respectively--to receptions and luncheons the companies sponsored. Pfizer's Jeff Kindler (photo) and Amgen's Kevin Sharer (photo) participated in a health roundtable. And at a PhRMA-sponsored brunch, Merck CEO Richard Clark (photo) and AstraZeneca's Brennan mingled with the invitation-only crowd.
And tonight, when Barack Obama accepts the Democratic nomination, Pfizer folks will be on hand in coveted skybox seats reserved for those donors who've given more than $1 million. Let's see who turns up for John McCain's Republican star turn next week.
- read the WSJ Health Blog post
- see the FDA Legislative Watch piece
- get the skybox article from the Dallas Morning News
Related Articles:
Pharma for Obama, but neither candidate loves pharma
Dems still in the pharma-contribution lead
Dems beat out Republicans for life sciences cash
Pharma backs Barack with money, votes
The 2008 Election: What does it mean for drugmakers?
Obama, McCain united against drug costs
Pharma backs Dems 51 to 49
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





